Loading insider details...
Beta
Latest Form 4 (Aug 20, 2026): Sale of 551 KROS shares, $5.7K.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Aug 20, 2026 | Keros Therapeutics, Inc. (KROS) | Sale | 551 | $5.7K |
| Jun 23, 2026 | NOVAVAX INC (NVAX) | Grant/Award | 21,270 | n/a |
| Jun 15, 2026 | Keros Therapeutics, Inc. (KROS) | Sale | 550 | $5.5K |
| Jun 9, 2026 | Coherus Oncology, Inc. (CHRS) | Grant/Award | 30,000 | n/a |
| Apr 28, 2026 | NOVAVAX INC (NVAX) | Exercise/Conversion | 9,520 | n/a |
| Mar 11, 2026 | Keros Therapeutics, Inc. (KROS) | Grant/Award | 13,215 | n/a |
| Aug 22, 2025 | Lyell Immunopharma, Inc. (LYEL) | Grant/Award | 8,000 | n/a |
| Aug 14, 2025 | Lyell Immunopharma, Inc. (LYEL) | Sale | 131 | $1.4K |
| Jun 13, 2025 | Coherus Oncology, Inc. (CHRS) | Grant/Award | 112,000 | n/a |
| Apr 29, 2025 | NOVAVAX INC (NVAX) | Grant/Award | 42,840 | n/a |